Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
Br J Cancer
    November 2017
  1. GOEL A
    IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  2. CODONY-SERVAT J, Cuatrecasas M, Asensio E, Montironi C, et al
    Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  3. GOEY KKH, Elias SG, Hinke A, van Oijen MGH, et al
    Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  4. COOPER JA, Parsons N, Stinton C, Mathews C, et al
    Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.
    Br J Cancer. 2017 Nov 2. doi: 10.1038/bjc.2017.
    >> Share

    October 2017
  5. MURAKAMI T, Kikuchi H, Ishimatsu H, Iino I, et al
    Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis.
    Br J Cancer. 2017;117:1360-1370.
    >> Share

  6. RUZZO A, Graziano F, Galli F, Galli F, et al
    Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Br J Cancer. 2017;117:1269-1277.
    >> Share

  7. HOU L, Zhu D, Liang Y, Tian X, et al
    Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    >> Share

  8. THERKILDSEN C, Ladelund S, Smith-Hansen L, Lindberg LJ, et al
    Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    >> Share

  9. GOLLINS S, West N, Sebag-Montefiore D, Myint AS, et al
    Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
    Br J Cancer. 2017;117:1286-1294.
    >> Share

  10. LETELLIER E, Schmitz M, Ginolhac A, Rodriguez F, et al
    Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    >> Share

  11. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    >> Share

    September 2017
  12. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    >> Share

  13. BROWN JC, Zemel BS, Troxel AB, Rickels MR, et al
    Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    >> Share

  14. GIAMPIERI R, Puzzoni M, Daniele B, Ferrari D, et al
    First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) tr
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    >> Share

  15. MATSUMOTO A, Arcaroli J, Chen Y, Gasparetto M, et al
    Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    >> Share

  16. SCHUBERT SA, Ruano D, Elsayed FA, Boot A, et al
    Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.
    Br J Cancer. 2017;117:876-884.
    >> Share

    August 2017
  17. FOWLER H, Belot A, Njagi EN, Luque-Fernandez MA, et al
    Persistent inequalities in 90-day colon cancer mortality: an English cohort study.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    >> Share

  18. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    >> Share

  19. ALLARD MA, Adam R, Giuliante F, Lapointe R, et al
    Long-term outcomes of patients with 10 or more colorectal liver metastases.
    Br J Cancer. 2017;117:604-611.
    >> Share

  20. LEVI F, Karaboue A, Saffroy R, Desterke C, et al
    Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  21. YUAN C, Bao Y, Sato K, Nimptsch K, et al
    Influence of dietary insulin scores on survival in colorectal cancer patients.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  22. YANG SS, Li XM, Yang M, Ren XL, et al
    FMNL2 destabilises COMMD10 to activate NF-kappaB pathway in invasion and metastasis of colorectal cancer.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  23. YUAN Z, Baker K, Redman MW, Wang L, et al
    Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.
    Br J Cancer. 2017 Aug 15. doi: 10.1038/bjc.2017.
    >> Share

  24. TORRING ML, Murchie P, Hamilton W, Vedsted P, et al
    Evidence of advanced stage colorectal cancer with longer diagnostic intervals: a pooled analysis of seven primary care cohorts comprising 11 720 patients in five countries.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    >> Share

  25. ZHU Y, Wang PP, Zhai G, Bapat B, et al
    Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    >> Share

    July 2017
  26. BHATTACHARYA R, Fan F, Wang R, Ye X, et al
    Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    >> Share

  27. WALKER AK, Kartsonaki C, Collantes E, Nicholson J, et al
    No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.
    Br J Cancer. 2017;117:322-325.
    >> Share

  28. KNUDSEN MD, Berstad P, Hjartaker A, Gulichsen EH, et al
    Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening.
    Br J Cancer. 2017 Jul 13. doi: 10.1038/bjc.2017.
    >> Share

  29. GASH KJ, Chambers AC, Cotton DE, Williams AC, et al
    Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.
    Br J Cancer. 2017;117:210-219.
    >> Share

  30. ALONSO MH, Ausso S, Lopez-Doriga A, Cordero D, et al
    Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    >> Share

    June 2017
  31. LIAO Q, Li R, Zhou R, Pan Z, et al
    LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    >> Share

  32. ODDO D, Siravegna G, Gloghini A, Vernieri C, et al
    Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
    Br J Cancer. 2017 Jun 27. doi: 10.1038/bjc.2017.
    >> Share

  33. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    >> Share

  34. CHAKRABARTY S, Varghese VK, Sahu P, Jayaram P, et al
    Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
    Br J Cancer. 2017;117:136-143.
    >> Share

  35. HATA T, Takemasa I, Takahashi H, Haraguchi N, et al
    Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    >> Share

  36. VAN EGGERMOND AM, Schaapveld M, Janus CP, de Boer JP, et al
    Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    >> Share

  37. DEMURTAS L, Puzzoni M, Giampieri R, Ziranu P, et al
    The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    >> Share

  38. MARIANI S, Bertero L, Osella-Abate S, Di Bello C, et al
    Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene.
    Br J Cancer. 2017 Jun 15. doi: 10.1038/bjc.2017.
    >> Share

  39. ALVI MA, Loughrey MB, Dunne P, McQuaid S, et al
    Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
    Br J Cancer. 2017 Jun 8. doi: 10.1038/bjc.2017.
    >> Share

  40. BENTON SC, Butler P, Allen K, Chesters M, et al
    GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project.
    Br J Cancer. 2017;116:1551-1557.
    >> Share

  41. SIDDIQUI MRS, Simillis C, Hunter C, Chand M, et al
    A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases.
    Br J Cancer. 2017;116:1513-1519.
    >> Share

    May 2017
  42. ALNABULSI A, Swan R, Cash B, Alnabulsi A, et al
    The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    >> Share

  43. FREISLING H, Arnold M, Soerjomataram I, O'Doherty MG, et al
    Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe.
    Br J Cancer. 2017;116:1486-1497.
    >> Share

  44. GRAY RT, Loughrey MB, Bankhead P, Cardwell CR, et al
    Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
    Br J Cancer. 2017 May 18. doi: 10.1038/bjc.2017.
    >> Share

  45. MOUNCE LTA, Price S, Valderas JM, Hamilton W, et al
    Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    >> Share

  46. DYER KE, Dumenci L, Siminoff LA, Thomson MD, et al
    The contribution of body mass index to appraisal delay in colorectal cancer diagnosis: a structural equation modelling study.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    >> Share

    April 2017
  47. HIRST Y, Skrobanski H, Kerrison RS, Kobayashi LC, et al
    Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    >> Share

  48. CALEGARI MA, Inno A, Monterisi S, Orlandi A, et al
    A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    >> Share

  49. PARK JH, van Wyk H, Roxburgh CSD, Horgan PG, et al
    Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    >> Share

  50. GUREN TK, Thomsen M, Kure EH, Sorbye H, et al
    Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    >> Share

  51. YOKOI K, Yamashita K, Ishii S, Tanaka T, et al
    Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer.
    Br J Cancer. 2017;116:1046-1056.
    >> Share

  52. GHUMAN S, Van Hemelrijck M, Garmo H, Holmberg L, et al
    Serum inflammatory markers and colorectal cancer risk and survival.
    Br J Cancer. 2017 Apr 4. doi: 10.1038/bjc.2017.
    >> Share

    March 2017
  53. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    >> Share

  54. FURLAN D, Trapani D, Berrino E, Debernardi C, et al
    Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis.
    Br J Cancer. 2017;116:793-801.
    >> Share

  55. BAE JM, Kim JH, Kwak Y, Lee DW, et al
    Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    >> Share

  56. GOSHEN R, Mizrahi B, Akiva P, Kinar Y, et al
    Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    >> Share

    February 2017
  57. SCHIFFMANN LM, Brunold M, Liwschitz M, Goede V, et al
    A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
    Br J Cancer. 2017;116:600-608.
    >> Share

  58. JONES RP, Sutton PA, Evans JP, Clifford R, et al
    Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    >> Share

  59. LECLERC D, Pham DN, Levesque N, Truongcao M, et al
    Oncogenic role of PDK4 in human colon cancer cells.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    >> Share

  60. ENGLINGER B, Mair M, Miklos W, Pirker C, et al
    Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.
    Br J Cancer. 2017;116:489-500.
    >> Share

  61. CARTER JV, Galbraith NJ, Yang D, Burton JF, et al
    Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    >> Share

    January 2017
  62. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    >> Share

  63. CREAVIN B, Ryan E, Martin ST, Hanly A, et al
    Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
    Br J Cancer. 2017;116:169-174.
    >> Share

  64. JONES CM, Goh V, Sebag-Montefiore D, Gilbert DC, et al
    Biomarkers in anal cancer: from biological understanding to stratified treatment.
    Br J Cancer. 2017;116:156-162.
    >> Share

  65. MARMORINO F, Salvatore L, Barbara C, Allegrini G, et al
    Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Br J Cancer. 2017;116:318-323.
    >> Share

  66. AQUINA CT, Mohile SG, Tejani MA, Becerra AZ, et al
    The impact of age on complications, survival, and cause of death following colon cancer surgery.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    >> Share

    December 2016
  67. CRISTOBAL I, Torrejon B, Madoz-Gurpide J, Rojo F, et al
    Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    >> Share

  68. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    Reply: Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    >> Share

  69. VAN DER VLUGT M, Grobbee EJ, Bossuyt PM, Bongers E, et al
    Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    >> Share

    November 2016
  70. RENNERT G
    Reproductive factors, hormones and colorectal cancer-still unresolved.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    >> Share

  71. MURPHY N, Xu L, Zervoudakis A, Xue X, et al
    Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    >> Share

  72. DE SMEDT L, Palmans S, Andel D, Govaere O, et al
    Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    Br J Cancer. 2016 Nov 24. doi: 10.1038/bjc.2016.
    >> Share

  73. DEN UIL SH, Coupe VM, Linnekamp JF, van den Broek E, et al
    Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    >> Share

  74. HE GY, Hu JL, Zhou L, Zhu XH, et al
    The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    >> Share

  75. JIA M, Jansen L, Walter V, Tagscherer K, et al
    No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    >> Share

    October 2016
  76. MOSKAL A, Freisling H, Byrnes G, Assi N, et al
    Main nutrient patterns and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    >> Share

  77. KARTHAUS M, Hofheinz RD, Mineur L, Letocha H, et al
    Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    >> Share

  78. BLINMAN P, Mileshkin L, Khaw P, Goss G, et al
    Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    >> Share

  79. KIM TW, Elme A, Kusic Z, Park JO, et al
    A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    >> Share

    September 2016
  80. MARZI L, Combes E, Vie N, Ayrolles-Torro A, et al
    FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    >> Share

  81. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    >> Share

  82. ROGERS AC, Winter DC, Heeney A, Gibbons D, et al
    Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    >> Share

    August 2016
  83. FARSHIDFAR F, Weljie AM, Kopciuk KA, Hilsden R, et al
    A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Br J Cancer. 2016 Aug 25. doi: 10.1038/bjc.2016.
    >> Share

  84. RENZI C, Lyratzopoulos G, Card T, Chu TP, et al
    Do colorectal cancer patients diagnosed as an emergency differ from non-emergency patients in their consultation patterns and symptoms? A longitudinal data-linkage study in England.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    >> Share

  85. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    >> Share

  86. ROSATO V, Guercio V, Bosetti C, Negri E, et al
    Mediterranean diet and colorectal cancer risk: a pooled analysis of three Italian case-control studies.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    >> Share

  87. LIGI D, Mannello F
    Do matrix metalloproteinases represent reliable circulating biomarkers in colorectal cancer?
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    >> Share

  88. BEALE G, Haagensen EJ, Thomas HD, Wang LZ, et al
    Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    >> Share

  89. WALTER FM, Emery JD, Mendonca S, Hall N, et al
    Symptoms and patient factors associated with longer time to diagnosis for colorectal cancer: results from a prospective cohort study.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    >> Share

    July 2016
  90. DREWES JL, Housseau F, Sears CL
    Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy.
    Br J Cancer. 2016 Jul 5. doi: 10.1038/bjc.2016.
    >> Share

    June 2016
  91. JARVIS D, Mitchell JS, Law PJ, Palin K, et al
    Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    >> Share

  92. STAFF S, Aaltonen M, Huhtala H, Pylvanainen K, et al
    Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    >> Share

  93. PILERI P, Campagnoli S, Grandi A, Parri M, et al
    FAT1: a potential target for monoclonal antibody therapy in colon cancer.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    >> Share

  94. BENITEZ-MAJANO S, Fowler H, Maringe C, Di Girolamo C, et al
    Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    >> Share

  95. CHA Y, Kim KJ, Han SW, Rhee YY, et al
    Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Br J Cancer. 2016 Jun 16. doi: 10.1038/bjc.2016.
    >> Share

  96. VAN WYK HC, Park JH, Edwards J, Horgan PG, et al
    The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    >> Share

  97. KONDO T, Okabayashi K, Hasegawa H, Tsuruta M, et al
    The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    >> Share

  98. LEE MS, McGuffey EJ, Morris JS, Manyam G, et al
    Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
    Br J Cancer. 2016 Jun 7. doi: 10.1038/bjc.2016.
    >> Share

    May 2016
  99. VAYRYNEN SA, Vayrynen JP, Klintrup K, Makela J, et al
    Clinical impact and network of determinants of tumour necrosis in colorectal cancer.
    Br J Cancer. 2016 May 19. doi: 10.1038/bjc.2016.
    >> Share

    April 2016
  100. JOHNSON SP, Ramasawmy R, Campbell-Washburn AE, Wells JA, et al
    Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling.
    Br J Cancer. 2016;114:897-904.
    >> Share

    March 2016
  101. POTTEGARD A, Ennis ZN, Hallas J, Jensen BL, et al
    Long-term use of lithium and risk of colorectal adenocarcinoma: a nationwide case-control study.
    Br J Cancer. 2016;114:571-5.
    >> Share

    February 2016
  102. MAX N, Harbaum L, Pollheimer MJ, Lindtner RA, et al
    Tumour budding with and without admixed inflammation: two different sides of the same coin?
    Br J Cancer. 2016;114:368-71.
    >> Share

  103. LOMAKINA ME, Lallemand F, Vacher S, Molinie N, et al
    Arpin downregulation in breast cancer is associated with poor prognosis.
    Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.
    >> Share

  104. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    >> Share

  105. KEARNS B, Whyte S, Seaman HE, Snowball J, et al
    Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm.
    Br J Cancer. 2016;114:327-33.
    >> Share

  106. RAINE R, Duffy SW, Wardle J, Solmi F, et al
    Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
    Br J Cancer. 2016;114:321-6.
    >> Share

    January 2016
  107. KIM SA, Inamura K, Yamauchi M, Nishihara R, et al
    Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
    Br J Cancer. 2016;114:199-206.
    >> Share

  108. GILBERT DC, Serup-Hansen E, Linnemann D, Hogdall E, et al
    Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
    Br J Cancer. 2016;114:134-7.
    >> Share

  109. KEUM N, Cao Y, Lee DH, Park SM, et al
    Male pattern baldness and risk of colorectal neoplasia.
    Br J Cancer. 2016;114:110-7.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016